Table 4 Olanzapine plasma concentrations at study endpoint for the olanzapine long-acting injection and olanzapine oral studies
Study and Treatment | n | Mean at endpoint (ng/mL) | SD | Minimum | Maximum |
|---|---|---|---|---|---|
OLZ LAI Study | |||||
405 mg/4 weeks olanzapine LAI | 39 | 13.4 | 7.8 | 5.9 | 56.0 |
210 mg/2 weeks olanzapine LAI | 55 | 18.3 | 9.4 | 5.5 | 44.7 |
300 mg/2 weeks olanzapine LAI | 56 | 24.3 | 11.6 | 9.3 | 87.6 |
Oral Study 1 | |||||
5 ± 2.5 mg/day olanzapine | 63 | 10.3 | 8.0 | 0.4 | 36.9 |
10 ± 2.5 mg/day olanzapine | 62 | 18.4 | 12.1 | 0.4 | 63.2 |
15 ± 2.5 mg/day olanzapine | 63 | 30.6 | 22.7 | 0.5 | 108.1 |
Oral Study 2 | |||||
1 mg/day olanzapine | 75 | 1.7 | 1.9 | 0.3 | 16.0 |
5 ± 2.5 mg/day olanzapine | 78 | 9.1 | 5.9 | 0.5 | 37.0 |
10 ± 2.5 mg/day olanzapine | 76 | 16.8 | 11.5 | 0.3 | 64.3 |
15 ± 2.5 mg/day olanzapine | 75 | 26.9 | 19.2 | 1.2 | 99.8 |
Oral Study 3 | |||||
1 mg/day olanzapine | 51 | 1.5 | 0.8 | 0.0 | 3.2 |
10 mg/day olanzapine | 48 | 20.7 | 17.1 | 0.3 | 93.0 |